Table 1 Comparison of Biobanks and Phenotypes Across the eMERGE sites
Site | Biobank design | Biobank size and demographics | Phenotypic outcomes |
|---|---|---|---|
Marshfield | Population-based | 20,000; 98% Caucasian, mean age 48, range 18-102 | Low HDL cholesterol, cataract (n = 3968) Secondary: diabetic retinopathy |
Mayo Clinic | PAD cases identified from the Mayo non-invasive vascular laboratory database; control subjects without PAD identified from the Cardiovascular Health Clinic | 1687 cases (mean age 65) and 1725 controls (mean age 60) | Peripheral arterial disease (PAD) (n = 3412); Secondary: red blood cell indices |
Northwestern | Outpatient clinic and hospital-based | Approximately 10,000; 12% African American, 8% Hispanic; Mean age 50, range 18 - 90+ | Primary: type II diabetes (n = 3531); Secondary: lipids and height |
Group Health | ACT Study Cohort of aged 65 and olderrandomly sampled from an HMO all known not to be demented at enrollment and followed for development of dementia, and Alzheimer's Disease (source of cases and controls) ADPR: Alzheimer's disease cases from a model incidence case registry (source of cases) | Approximately 4000 persons over age 65 from ACT Study | Alzheimer Disease (n = 3390), carotid artery stenosis; Secondary: statin adverse events |
Vanderbilt | Use of discarded blood/non-human subjects linked to electronic medical records | Approximately 75,000; 70% Caucasian, 10% African American; mean age 53, range 18-100 | Electrocardiographic QRS duration (n = 3192); Secondary: PheWAS |